Home > > > News

No Cancer Risk with ADHD Meds

Contrary to a previous concerns, new research shows ADHD medications don't increase genetic damage and cancer risk

Friday November 21st - 11:57am

A new study from Duke University Medical Center and the National Institutes of Health found that two popular medications for treating attention-deficit hyperactivity disorder (ADHD) -- methylphenidate (Ritalin LA and Concerta) and amphetamine (Adderall and Adderall XR) -- do not lead to an increased risk for developing cancer.

The study counters a previous one that reported an increase in genetic damage in children taking methylphenidate. The genetic damage is associated with an increased risk of cancer.

The new study used a larger sample of children, and did not find increased genetic abnormalities.

The study was published in the November online issue of the Journal of the American Academy of Child & Adolescent Psychiatry.

Read more about the study.

What do you think of this article? Share your comments on www.ADDConnect.com, ADDitude's community site. Check out the new ADHD Medication User Reviews and the ADHD Adults Support Group. Your fellow ADDers want to hear from you!

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018